ClinicalTrials.gg
CompletedNCT02761512Updated Aug 22, 2019

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer

A Phase 3 interventional study of CJ-12420 50 mg QD and CJ-12420 100 mg QD in Gastric Ulcer, sponsored by HK inno.N Corporation. Completed at 2 sites in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-08-22.

Sponsored by HK inno.N Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Stomach Ulcer with a site in Korea, Republic of — 2 open to participants now, 2 under way, 1 of them phase 3. Stomach Ulcer · Korea, Republic of.

Enrollment
6th of 17
306 · median 199
Started
2016
with 1 other
Phase 3
7 of 20
1 open now
Registered
11th of 20
by date
Lead sponsor
1 of 20
HK inno.N Corporation

Among the 20 studies in Stomach Ulcer with a site in Korea, Republic of, this one is the 6th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2016, is one of 7 in phase 3, and was the 11th registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

2 of the 20 studies in Stomach Ulcer with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Stomach Ulcer with a site in Korea, Republic of, or all of them as a file.
02

Study summary

To demonstrate non-inferiority of CJ-12420 to lansoprazole 30 mg capsule in terms of therapeutic efficacy, and to confirm safety of CJ-12420, after once daily oral administration of CJ-12420 50 mg, 100 mg or Lansoprazole 30 mg capsule in gastric ulcer patients.

Read the detailed description

This is a double blind, randomized, placebo-controlled, phase 3 study. Subjects will be randomly assigned to one of the three treatment groups (CJ-12420 50 mg, 100 mg or Lansoprazole 30 mg).

03

Conditions studied

  • Gastric Ulcer

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of 1 or more active gastric ulcers (≥3 mm \~ ≤30 mm using open forceps) according to the Sakita-Miwa classification (A1 or A2 stage) from upper GI endoscopy at the same institution within 14 days prior to initiation of the product administration.

Exclusion criteria

Exclusion Criteria:

  1. Finding of gastrointestinal bleeding, esophageal stricture, ulcer stenosis, pyloric stenosis, esophageal gastric varices, Barrett's esophageal of >3 cm (long segment Barrett esophagus, LSBE), duodenal ulcer, intractable ulcer, digestive ulcer perforation or on upper GI endoscopy.
  2. Ulcer caused by an endoscopic surgery (e.g., ulcer after EMR/ESD)
  3. Requirement of persistent daily use of drugs that may cause an ulcer such as nonsteroidal anti-inflammatory drugs(NSAIDs) or aspirin during the course of the study
  4. Scheduled surgery requiring hospitalization or requirement of surgical treatment during study participation
  5. Subjects who participated in the other clinical trial within 4 weeks prior to randomization
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
306 participants (actual)

Study arms

  • Experimental
    CJ-12420 50 mg QD

    CJ-12420 50 mg, tablet, once daily, oral administration for up to 8 weeks

    Drug: CJ-12420 50 mg QD

  • Experimental
    CJ-12420 100 mg QD

    CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks

    Drug: CJ-12420 100 mg QD

  • Active comparator
    Lansoprazole 30 mg QD

    Lansoprazole 30 mg, capsule, once daily, oral administration for up to 8 weeks

    Drug: Lansoprazole 30 mg QD

Interventions

  • CJ-12420 50 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 50 mg.

    Also known as: Not yet decided

  • CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 100 mg.

    Also known as: Not yet decided

  • Lansoprazole 30 mg capsule will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of Lansoprazole 30 mg.

    Also known as: Lanston cap.

06

What researchers measure

Primary outcomes

  1. Cumulative healing rate of gastric ulcer at 8-week

    Time frame: 8 weeks

Secondary outcomes

  1. Healing rate of gastric ulcer at 4-week

    Time frame: 4 weeks

  2. Week 8 healing rates by H. pylori infection

    Time frame: 8 weeks

07

Study locations

2 sites
  • Catholic Univ. Seoul St. Mary Hospita
    Seoul, Korea, Republic of
  • Kyung Hee University Medical Center
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Jul 2018, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2016
First posted
May 4, 2016
StartActual
May 2016
Primary completionActual
Jul 26, 2018
CompletionActual
Dec 28, 2018
Last update
Aug 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02761512
Responsible party
Sponsor
First posted
May 4, 2016
Start date
May 2016
Primary completion
Jul 26, 2018
Completion
Dec 28, 2018
Last update
Aug 22, 2019

Study contacts

Myung Gyu Choi, M.D., Ph.D
principal investigator · Catholic Univ. Seoul St. Mary Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion